Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Baxter
Mallinckrodt
AstraZeneca
Merck

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Details for Biologics License Application: 125544

See Plans and Pricing

« Back to Dashboard

Summary for BLA: 125544
Tradename:INFLECTRA
Applicant:Celltrion Inc
Ingredient:infliximab-dyyb
Patents:1
Approval Date:Apr 05, 2016
Suppliers: see list1
Pharmacology for BLA: 125544

US Patents for BLA: 125544

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Celltrion Inc INFLECTRA infliximab-dyyb INJECTABLE;INJECTION 125544 001 2016-04-05   Start Trial RX
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson
Dow
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.